Every Form 4 that BlossomHill Therapeutics, Inc. (BLSM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BLSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLSM filings page.
For BlossomHill Therapeutics, Inc. (BLSM), director Carl L. Gordon, through OrbiMed-related entities, reported automatic conversion of 1,039,996 shares of Series A Preferred Stock and 1,049,283 shares of Series B Preferred Stock into the same number of BlossomHill common shares upon the closing of the company’s initial public offering on August 10, 2026, without payment of consideration. In addition, OrbiMed Private Investments VIII, LP purchased 625,000 BlossomHill common shares in the IPO at $16.00 per share, reported as indirectly owned. The filing states that OrbiMed entities may be deemed to have voting and investment power over these securities, and that Carl L. Gordon, OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC each disclaim beneficial ownership except to the extent of any pecuniary interest.
BlossomHill Therapeutics, Inc. (BLSM) reported insider activity by OrbiMed-affiliated entities in connection with its initial public offering on August 10, 2026. OrbiMed Private Investments VIII, LP converted 1,039,996 shares of Series A Preferred Stock and 1,049,283 shares of Series B Preferred Stock into an equal number of common shares upon the IPO closing, without payment of consideration. In addition, it purchased 625,000 common shares at 16.0000 per share in the IPO. The reported OrbiMed entities may be deemed to share voting and investment power over these securities through their control relationships and each disclaims beneficial ownership beyond its pecuniary interest.
BlossomHill Therapeutics, Inc. (BLSM) reported that director Carl L. Gordon received a grant of 23,904 Director Stock Options on August 6, 2026. The options have an exercise price of $16.00 per share and expire on August 5, 2036. According to the vesting terms, 1/36 of the shares vest in equal monthly installments over three years following August 6, 2026. A footnote states that, under an agreement with OrbiMed Advisors LLC, Gordon is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC, which will ensure they are provided to OrbiMed Private Investments VIII, LP.
BlossomHill Therapeutics, Inc. (BLSM) insider group associated with Cormorant funds reported several equity changes. On August 10, 2026, Cormorant-related funds converted Series A and Series B Preferred Stock into an equal number of Common Stock shares in connection with the closing of the company’s initial public offering. The Master Fund also purchased 312,500 Common Stock shares at $16.00 per share, increasing its indirect position. Separately, on August 6, 2026, director and ten percent owner Bihua Chen received a stock option grant for 23,904 shares with a $16.00 exercise price, vesting monthly over three years and expiring on August 5, 2036. The reporting persons state that they may be deemed beneficial owners only to the extent of their pecuniary interest in the reported shares.
BlossomHill Therapeutics, Inc. (BLSM) reported that on August 10, 2026, 578,524 shares of Series B Preferred Stock held indirectly through Brahma BlossomHill Partners, LLC automatically converted into 578,524 shares of Common Stock upon the closing of BlossomHill Therapeutics’ initial public offering, with the preferred shares then reduced to zero. These securities are held of record by Brahma BlossomHill Partners, LLC, which is managed by an entity founded and led by director Sundeep Agrawal; he may be deemed to have voting or investment power but expressly disclaims beneficial ownership.
Separately, on August 6, 2026, Agrawal received a director stock option to purchase 23,904 shares of Common Stock at an exercise price of $16.00 per share, expiring on August 5, 2036. According to the vesting terms, 1/36 of the option shares vest in equal monthly installments over three years following August 6, 2026.